login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
MAXCYTE INC (MXCT) Stock News
USA
- NASDAQ:MXCT -
US57777K1060
-
Common Stock
1.63
USD
+0.02 (+1.24%)
Last: 10/20/2025, 10:42:46 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
MXCT Latest News, Press Relases and Analysis
All
Press Releases
12 days ago - By: MaxCyte, Inc
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
12 days ago - By: MaxCyte, Inc
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
14 days ago - By: MaxCyte, Inc
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
14 days ago - By: MaxCyte, Inc
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
2 months ago - By: The Motley Fool
MaxCyte (MXCT) Q2 Revenue Drops 18%
3 months ago - By: Benzinga
- Mentions:
OEC
VTLE
DIN
INSE
...
Earnings Scheduled For August 6, 2025
a month ago - By: MaxCyte, Inc
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
a month ago - By: MaxCyte, Inc
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
2 months ago - By: Yahoo Finance
- Mentions:
ACET
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio
6 months ago - By: Benzinga
- Mentions:
XPER
EMR
BLZE
ERII
...
Earnings Scheduled For May 7, 2025
2 months ago - By: Zacks Investment Research
- Mentions:
IOVA
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates
2 months ago - By: MaxCyte, Inc
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
3 months ago - By: MaxCyte, Inc
MaxCyte Signs Platform License Agreement with Adicet Bio
3 months ago - By: MaxCyte, Inc
MaxCyte Signs Platform License Agreement with Adicet Bio
3 months ago - By: MaxCyte, Inc
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
3 months ago - By: MaxCyte, Inc
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
3 months ago - By: MaxCyte, Inc
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
3 months ago - By: MaxCyte, Inc
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
4 months ago - By: MaxCyte, Inc
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
4 months ago - By: MaxCyte, Inc
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
5 months ago - By: Yahoo Finance
- Mentions:
DHI
CMG
MaxCyte, Inc. (MXCT): A Bull Case Theory
6 months ago - By: Zacks Investment Research
- Mentions:
CUE
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
6 months ago - By: MaxCyte, Inc
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
6 months ago - By: MaxCyte, Inc
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
6 months ago - By: MaxCyte, Inc
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
7 months ago - By: MaxCyte, Inc
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
8 months ago - By: MaxCyte, Inc
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
8 months ago - By: MaxCyte, Inc
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
9 months ago - By: MaxCyte, Inc
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
Please enable JavaScript to continue using this application.